NEW YORK, June 15, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Richard Christopher, Vice President, Finance and Chief Financial Officer, will present a corporate overview at the Inaugural Marcum MicroCap Conference on June 20th at the Roosevelt Hotel in New York City. Mr. Christopher is scheduled to present at 11:30am ET.
Interested parties can access a live webcast of the presentation on DUSA's website at www.dusapharma.com, as well as on the conference website at http://execvid.com/marcum-microcap-conference-2012. For full conference details, please click here.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform. Levulan® Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% plus blue light illumination using DUSA's BLU-U® Blue Light Photodynamic Therapy Illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.
CONTACT: Chad Rubin, The Trout Group LLC, 646-378-2947